Plateauing on Wegovy: what's normal, what isn't, and what happens next

Step 1: recognise what a Wegovy plateau actually is

If you've been losing weight steadily and the scales have stopped moving for two to four weeks, it's understandable to worry that something has gone wrong. It hasn't, and you're almost certainly not alone in feeling that frustration.

A plateau on Wegovy is a period during which weekly weight readings remain broadly flat despite continuing the medicine and maintaining your usual habits. This is distinct from a brief wobble caused by fluid retention, a heavy meal the night before, or hormonal shifts across a menstrual cycle. A genuine plateau tends to persist across multiple weigh-ins over several weeks.

Semaglutide works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, reducing how much food feels comfortable to eat. In the STEP 1 trial, published in the New England Journal of Medicine, participants using 2.4 mg semaglutide lost around fifteen per cent of body weight on average over 68 weeks — but that loss was not linear. The rate of change slowed substantially in the second half of the trial. A plateau, in other words, was built into the data from the start. The body defends a new lower weight by adjusting its resting metabolism, altering hunger hormones, and becoming more efficient with energy. This is metabolic adaptation, and it happens with all effective weight-loss interventions, not just semaglutide.

The NHS semaglutide medicines page notes that individual responses vary; some people lose weight faster early on, others more gradually throughout. Both patterns are within normal range.

Step 2: look at the factors that influence whether the plateau lifts

Not all plateaus are the same, and several practical factors affect whether yours is likely to resolve on its own or benefit from adjustment.

Dose stage. If you're still working through the titration schedule (moving through 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg toward 2.4 mg) a plateau at a lower dose is quite different from one reached after weeks or months on the full maintenance dose. Stepping up to the next prescribed dose often restarts progress, though that timing is your prescriber's call, not yours to manage independently.

Dietary drift. Semaglutide reduces appetite significantly, but it doesn't prevent the gradual return of old eating patterns as the novelty of early treatment fades. Protein adequacy matters here: eating enough protein helps preserve lean muscle mass during weight loss, and muscle is metabolically active tissue. If your protein intake has quietly slipped, that can contribute to a plateau. A note worth reading is the NHS healthy weight guidance, which covers the diet basics that support any weight-management approach.

Activity levels. Weight loss alone tends to reduce overall movement, lighter bodies burn fewer calories at rest, and fatigue from a calorie deficit can reduce spontaneous activity. Strength-based exercise is particularly useful during a plateau because it maintains or builds muscle, counteracting some of the metabolic slowdown.

Sleep and stress. Poor sleep and sustained psychological stress both raise cortisol, which promotes fat storage and can stall weight loss even when dietary intake is well controlled. These are worth considering honestly before assuming the medicine is the problem.

For a broader look at what's happening during this phase of treatment, our guide to the Wegovy plateau covers the physiology in more depth, and if you want to understand why you've hit a plateau on Wegovy and what typically comes next, that page walks through what to expect and why it happens. If you've already been through this phase before, our page on what to do when you've plateaued on Wegovy more than once addresses the particular challenges that repeat plateaus can bring.

Step 3: understand the clinical thresholds that guide what happens next

NICE's appraisal of semaglutide (Wegovy) sets a clear clinical checkpoint: if a person has lost less than five per cent of their starting body weight after six months on the maintenance dose, continuing treatment should be reviewed. This five per cent threshold appears in NICE technology appraisal TA875, which covers semaglutide for weight management in adults.

That guideline applies to NHS-supervised treatment, but it reflects a broader clinical principle: the medicine needs to be doing meaningful work to justify continuing. If you're at or above the maintenance dose and have been for some months with no movement at all, that's a conversation to have with your prescriber, not a reason to quietly stop or push ahead without support.

On the other hand, if you've lost, say, twelve per cent over five months and are now in a two-week flat patch, you're almost certainly not at a clinical plateau, you're in a normal consolidation phase. The body needs time to recalibrate before losing more. Patience, in that scenario, is genuinely part of the treatment.

It's also worth knowing that Wegovy's highest licensed dose in the UK is now 7.2 mg, following MHRA approval of a dedicated single-dose pen in April 2026. Some people who have plateaued at 2.4 mg may find a higher dose is appropriate, subject entirely to clinical assessment. Dose decisions are made by your prescriber, based on your full health picture, not by working through a list of options yourself. If you want to explore where you stand, the practical guide on responding to a Wegovy plateau covers the steps worth taking.

Step 4: decide whether to get clinical input now

Most plateaus resolve with time, a small adjustment to habits, or a dose step managed by a prescriber. Some do not, and that's important information rather than a failure.

If you're at maintenance dose and have seen no weight change for more than eight weeks, if you've noticed appetite returning strongly, or if you're uncertain whether your dose progression has been clinically reviewed recently, it's worth speaking to a prescriber. For people currently on Wegovy through a private service, a review doesn't have to mean starting over. It means a trained clinician looking at your current dose, your progress curve, and your circumstances together.

At nume, a GPhC-registered prescriber personally reviews every repeat order before it's dispensed, which means ongoing monitoring is part of what the service provides, not something you have to chase separately. If you'd like clinical input on where your treatment stands, you can speak to our prescribers through a free consultation. For general questions about how Wegovy works before committing to that step, the Wegovy treatment overview is a useful starting point, and the timeline guide puts the plateau phase in context of the full treatment arc. You can also browse common questions about the service if you want more background first.